OTC Markets OTCPK - Delayed Quote • USD
Humanigen, Inc. (HGENQ)
At close: May 28 at 12:39 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.43 | -0.23 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | 200k | -- |
| Low Estimate | -- | -- | 200k | -- |
| High Estimate | -- | -- | 200k | -- |
| Year Ago Sales | 1.04M | 221k | 2.51M | 200k |
| Sales Growth (year/est) | -- | -- | -92.00% | -- |
Earnings History
| CURRENCY IN USD | 6/30/2022 | 9/30/2022 | 12/31/2022 | 3/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.3 | -0.18 | -0.06 | -0.06 |
| EPS Actual | -0.43 | -0.23 | 0.05 | -0.04 |
| Difference | -0.13 | -0.05 | 0.11 | 0.02 |
| Surprise % | -43.30% | -27.80% | 183.30% | 33.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.04 | -0.04 | -0.15 | -0.09 |
| 30 Days Ago | -0.04 | -0.04 | -0.15 | -0.09 |
| 60 Days Ago | -0.04 | -0.04 | -0.15 | -0.09 |
| 90 Days Ago | -0.04 | -0.04 | -0.15 | -0.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | HGENQ | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 7.90% |
| Next Qtr. | -- | -- | -- | 10.20% |
| Current Year | -- | -- | -- | 4.80% |
| Next Year | -- | -- | -- | 12.50% |
| Next 5 Years (per annum) | 12.50% | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Credit Suisse: Underperform | 4/3/2023 |
| Downgrade | Roth Capital: Buy to Neutral | 7/13/2022 |
| Downgrade | Cantor Fitzgerald: Overweight to Neutral | 7/13/2022 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 7/13/2022 |
| Downgrade | Jefferies: Buy to Hold | 9/10/2021 |
| Downgrade | JP Morgan: Neutral to Underweight | 9/9/2021 |
Related Tickers
PHGEW
0.0098
-10.09%
GNMSF Genmab A/S
289.94
+7.50%
296.SG CytoDyn Inc
0.2600
+20.37%
DOMH Dominari Holdings Inc.
2.1300
-1.84%
GMDAQ Gamida Cell Ltd.
0.0170
+2.41%
TRAW Traws Pharma, Inc.
0.6044
-2.63%
MEIP MEI Pharma, Inc.
3.0657
-1.11%
PHGE BiomX Inc.
0.3601
+5.91%
CLDI Calidi Biotherapeutics, Inc.
0.2591
+13.24%
KURA Kura Oncology, Inc.
21.49
+1.51%